Previous 10 | Next 10 |
--Investigator’s Retrospective Analysis Published in the Journal of Urology Provides Protocol for Antegrade Administration of Jelmyto, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer-- UroGen Pharma Ltd. (Nasdaq:...
UroGen Pharma (URGN -3.2%) began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The study is expected to enroll ~220 patients across 90 sites by the end of 2022....
-- ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial -- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initia...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in January: 40 th Annual J.P...
Study explores opportunity to shift from clinic to home instillation of this promising non-surgical treatment Potential to transform care and access to treatment for this growing patient population UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to b...
UroGen Pharma (NASDAQ:URGN) granted 13 new employees inducement restricted stock units (“RSUs”) in connection with their employment with UroGen. Up to 53,000 shares of UroGen’s common stock are issuable upon the vesting and settlement of the RSUs. The RSUs will...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this event. For further details see: Urogen Pharma (URGN) Investor Presentation - Slideshow
UroGen Pharma Ltd. (URGN) Q3 2021 Earnings Conference Call November 15, 2021, 10:00 AM ET Company Participants Lee Roth - IR Liz Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - CFO Conference Call Participants Chris Ho...
UroGen Pharma (URGN -18.0%) has recorded the biggest intra-day loss since March 2020 after the company reported lower-than-expected third-quarter financials for 2021 and full year guidance for revenue. Quarterly revenue grew more than 200% YoY from the first full quarter following the la...
Gainers: Creative Realities (NASDAQ:CREX) +128%. Casper Sleep (NYSE:CSPR) +86%. Siyata Mobile (NASDAQ:SYTA) +33%. Patriot National Bancorp (NASDAQ:PNBK) +35%. SilverSun Technologies (NASDAQ:SSNT) +26%. The Vita CoCo (NASDAQ:COCO) +24%. Trio-Tech (NYSE:TRT) +24%. Gores Guggenheim (NASDAQ:GGPI)...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...